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Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv
enhances targeting selectivity and induces a therapeutic effect
in vitro
MK Robinson*,1, KM Hodge1, E Horak1, A˚L Sundberg1, M Russeva1, CC Shaller1, M von Mehren1, I Shchaveleva1,
HH Simmons1, JD Marks2 and GP Adams*,1
1Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; 2Department of Anesthesia and Pharmaceutical Chemistry,
University of California, San Francisco, CA, USA
Inappropriate signalling through the EGFR and ErbB2/HER2 members of the epidermal growth factor family of receptor tyrosine
kinases is well recognised as being causally linked to a variety of cancers. Consequently, monoclonal antibodies specific for these
receptors have become increasingly important components of effective treatment strategies for cancer. Increasing evidence suggests
that ErbB3 plays a critical role in cancer progression and resistance to therapy. We hypothesised that co-targeting the preferred
ErbB2/ErbB3 heterodimer with a bispecific single-chain Fv (bs-scFv) antibody would promote increased targeting selectivity over
antibodies specific for a single tumour-associated antigen (TAA). In addition, we hypothesised that targeting this important
heterodimer could induce a therapeutic effect. Here, we describe the construction and evaluation of the A5-linker-ML3.9 bs-scFv
(ALM), an anti-ErbB3/ErbB2 bs-scFv. The A5-linker-ML3.9 bs-scFv exhibits selective targeting of tumour cells in vitro and in vivo that
co-express the two target antigens over tumour cells that express only one target antigen or normal cells that express low levels of
both antigens. The A5-linker-ML3.9 bs-scFv also exhibits significantly greater in vivo targeting of ErbB2‘þ ’/ErbB3‘þ ’ tumours than
derivative molecules that contain only one functional arm targeting ErbB2 or ErbB3. Binding of ALM to ErbB2‘þ ’/ErbB3‘þ ’ cells
mediates inhibition of tumour cell growth in vitro by effectively targeting the therapeutic anti-ErbB3 A5 scFv. This suggests both that
ALM could provide the basis for an effective therapeutic agent and that engineered antibodies selected to co-target critical functional
pairs of TAAs can enhance the targeting specificity and efficacy of antibody-based cancer therapeutics.
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Although many treatment options exist for metastatic breast
cancer, additional curative strategies are required. The develop-
ment of antibodies that target critical signalling pathways
implicated in cancer initiation and progression is one area
of active research focused on this concern. The ErbB family
(ErbB1/EGFR, ErbB2/HER2, ErbB3/HER3 and ErbB4/HER4) of
receptor tyrosine kinases (RTKs) is known to drive both formation
and progression of a number of commonly occurring cancers,
including breast cancer, due to the normal role of these RTKs
in regulating cell growth and survival (Yarden and Sliwkowski,
2001; Hynes and Lane, 2005). Therefore, these RTKs are important
targets for the development of new antibody-based therapeutics.
At present, the anti-ErbB2 monoclonal antibody (MAb) trastuzu-
mab is the only antibody approved for use against metastatic
breast cancer. Trastuzumab, most likely due to a multifaceted
mechanism (for review, see Hynes and Lane, 2005) is efficacious
against cancer that is driven by ERBB2 gene amplification
(Slamon et al, 2001). This subset of cancer is associated with poor
patient outcome due to enhanced tumour aggressiveness and high
risk of relapse (Slamon et al, 1989) but accounts for only 20– 30%
of the total patient population. Increased patient coverage is
necessary. A second anti-ErbB2 MAb, pertuzumab, binds to an
epitope in domain II of the extracellular domain (ECD) sterically
inhibiting the binding pocket necessary for receptor dimerisation
(Hynes and Lane, 2005). By preventing dimerisation, pertuzumab
effectively blocks ligand-dependent proliferation of non-gene-
amplified breast and prostate cancer cells in culture (Agus et al,
2002). These results have led to the initiation of clinical trials
in non-gene-amplified patient populations, although with limited
success to date (Gordon et al, 2006; Walshe et al, 2006; Agus et al,
2007; de Bono et al, 2007).
In contrast to eliciting a therapeutic effect by directly altering
signalling events, antibodies can be used to selectively deliver
cytotoxic payloads to cancer cells (for review, see Adams and
Weiner, 2005). However, tumour-associated antigens are often
expressed at lower levels on normal tissues and are known to
function as ‘off-site’ targets for therapeutic antibodies. For
example, acneform rash associated with cetuximab-dependent
inhibition of EGFR signalling in the skin is correlated with clinical
responses in colorectal cancer patients (Cunningham et al, 2004).
In some cases, targeting an antigen present in normal tissues can
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lead to significant toxicity or even death, particularly when a
cytotoxic immunoconjugate is employed (Pai et al, 1991; Knox
et al, 2000; Seidman et al, 2002). One possible mechanism to
enhance the therapeutic efficacy of MAb-based treatment is to
improve the targeting selectivity of these agents. Tumour targeting
of small, engineered antibodies is greatly influenced by the
functional affinity imparted through avid binding (Adams et al,
1993, 2006). We hypothesised that this contribution of functional
affinity could be exploited, through the use of bispecific antibodies
(bsAbs), to improve tumour uptake and targeting selectivity over
normal tissue that expresses only one (or low levels of both) target
antigen. Other groups have developed bsAb-based molecules that
simultaneously target two tumour-associated antigens such as
EGFR and insulin growth factor receptor (IGFR) (Lu et al, 2005) or
carcinoembryonic antigen (CEA) and ErbB2 (Dorvillius et al,
2002). However, there has been little evidence that bsAb-based
targeting strategies can be employed to enhance targeting
specificity.
On the basis of multiple lines of evidence, we hypothesised that
the ErbB2/ErbB3 heterodimer would be a valuable target for the
development of a bsAb for the treatment of breast cancer. First, the
ErbB2/ErbB3 heterodimer constitutes the most potent ErbB
signalling pair when measured in cell culture assays (Yarden and
Sliwkowski, 2001; Hynes and Lane, 2005). Second, expression of
either ErbB2 or ErbB3 is associated with poor prognosis in breast
cancer. Third, the receptors are frequently co-expressed in human
breast cancer (Gasparini et al, 1994; Naidu et al, 1998; Witton et al,
2003); Naidu et al (1998), in a 220 patient study, showed that
greater than 50% of all tumours expressed moderate to high levels
of either ErbB2 or ErbB3, with their co-expression being higher
than any other pair of ErbB family members. To that end, we
developed an anti-ErbB2/ErbB3 bispecific single-chain Fv mole-
cule. Here, we present both in vitro and in vivo evidence of its
selective targeting of cells that co-express both target antigens.
In addition, we demonstrate that the bispecific single chain-Fv
(bs-scFv) has intrinsic anti-cancer activity when measured in vitro
and that the anti-ErbB3 arm of the bs-scFv is responsible for
mediating this activity.
MATERIALS AND METHODS
Cell lines
The BT-474 (ATCC no. HTB-20), SK-OV-3 (ATCC no. HTB-77),
MDA-MB-468 (ATCC no. HTB-132), MCF10a (ATCC no. CRL-
10317) and B16-F0 (ATCC no. CRL-6233) cell lines were obtained
from the American Type Culture Collection (ATCC). MDA-361/
DYT2 is a derivative of MDA-MB-361 (ATCC no. HTB-27) and was
a kind gift from Dr D Yang (Georgetown University; Yang et al,
1998). All cells were maintained in DMEM supplemented with 10%
fetal bovine serum (FBS). MVM2 cells are a derivative of B16-F0
murine melanoma cells transfected to express full-length human
ErbB2 under control of the CMV promoter. The human cDNA of
ErbB2 was obtained from pSVHER2 (gift from Dr T Eberlein;
Yoshino et al, 1994) and subcloned into pLNCX as a 4.6 Kb HindIII
fragment to create pLNCX-HER2. pLNCX-ERBB2 was transfected
into B16-F0 cells through electroporation, and transfectants were
selected in DMEM supplemented with 10% FBS and 1.8 mg ml1
G418. Clones were expanded and cell surface expression of ErbB2
was confirmed by flow cytometry with mouse anti-ErbB2 MAb
520C9 (gift from Dr D Ring, Chiron Corporation) and goat anti-
mouse-FITC conjugated secondary antibody. The MVM2 clone
was selected on the basis of its high level of expression by flow
cytometry. Expression levels of ErbB2 and ErbB3 on each of the
cell lines used in this study were measured by quantitative flow
cytometry with the QuantiBrite System (Becton Dickinson) using
the manufacturer’s protocols. Anti-ErbB2 (Becton Dickinson, cat
no. 340552) and anti-ErbB3 (R&D, cat no. FAB3481P) conjugated
to a 1 : 1 ratio with phycoerythrin (PE) by the manufacturers were
used for monitoring expression levels with the mean of three
independent experiments reported in Table 1.
Construction of bs-scFv
The anti-ErbB3/anti-ErbB2 bs-scFv was created from the A5 anti-
ErbB3 (Horak et al, 2005) and ML3.9 anti-ErbB2 (Schier et al,
1996) scFvs using a multistep cloning strategy. Briefly, sense
(50oAATTCAGGTGCTGGTACTTCAGGTTCAGGTGCTTCAGGTG
AAGGTTCAGGTTCAA430) and anti-sense (50oAGCTTTGAACC
TGAACCTTCACCTGATGCACCTGAACCTGAAGTACCAGCACCT
G430) oligos encoding a peptide linker sequence (NSGAGTSGSG
ASGEGSGSKL) were hybridised and cloned into pET20b(þ )
(Novagen) as an EcoRI/HindIII fragment to create pET20b-L.
The anti-ErbB3 scFv was amplified from pSYN-A5 (Horak et al,
2005) by PCR with primers that encompassed the NcoI site at the
50-end of the gene and incorporated an in-frame EcoRI site at the
30-end of the gene. The fragment was subcloned into pET20b-L as
an NcoI/EcoRI fragment to create pET20b-AL. The ML3.9 scFv was
amplified from pSYN-ML3.9 (Schier et al, 1996) with primers that
incorporated in-frame HindIII and XhoI sites at the 50- and 30-ends
of the gene, respectively, and was then subcloned into pET20b-AL
as a HindIII/XhoI fragment to create pET20b-A5-linker-ML3.9
bs-scFv (ALM). The A5-linker-ML3.9 bs-scFv was then subcloned
into pSYN as an NcoI/NotI fragment. This construct (pSYN-ALM)
contains an XhoI site, 6XHIS tag and stop codon derived from the
pET20b(þ ) vector 50 to the pSYN-encoded NotI site. To facilitate
substitution of individual arms, the EcoRI and HindIII sites
present in the polylinker of pSYN-ALM were destroyed by
site-directed mutagenesis with the QuikChange Site-Directed
Mutagenesis kit (Stratagene) using the manufacturer’s protocols.
The ‘dead’ D3 scFv was isolated from a human phage-display
library (Yuan et al, 2006) and binds to an epitope formed by the
junction between a biotinylated peptide and streptavidin. Binding,
as measured by surface plasmon resonance (SPR) on a
BIAcore1000 (BIAcore, Piscataway, NJ, USA), requires the
presence of both the peptide and SA; binding cannot be competed
with either of the components alone. The D3 scFv was amplified by
PCR with primers that incorporate either in-frame NcoI/EcoRI or
HindIII/XhoI restriction sites and sublconed into pSYN-ALM to
create pSYN-DLM and pSYN-ALD.
Physical characterization of bs-scFvs
Bispecific-scFvs were expressed in Escherichia coli and purified by
sequential IMAC and size-exclusion chromatography essentially as
described (Robinson et al, 2005). Binding of the A5 and the ALM
bs-scFv to ErbB2 and ErbB3 ECDs was characterized by SPR using
ErbB2 and ErbB3 ECDs (Horak et al, 2005) as target antigens and
Table 1 Expression levels of ErbB2 and ErbB3 on cell lines
Cell line ErbB2 ErbB3
SK-OV-3 9.6 105 3.0 103
BT-474 7.6 105 5.1 104
MDA-361/DYT2 2.9 105 2.2 104
MDA-MB-468 o1 102 1.6 104
MCF10a 3.5 104 5.0 103
T-47D 5.2 104 ND
MDA-MB-231 2.8 104 ND
MVM2 3.5 105 NA
NA¼ not applicable, cell line is of murine origin and not expected to express human
ErbB3; ND¼ not tested. Expression levels were determined by quantitative flow
cytometry on the basis of the assumption that each antibody bound to two
receptors.
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methods described previously (Yuan et al, 2006). Extracellular
domains were diluted to 10 mg ml1 in 10 mM sodium acetate, pH
5.2, and approximately 200 RU of ECDs were immobilized onto
CM5 sensor chips through NHS-ester chemistry. Kinetic constants
for A5 were determined by passing serially diluted samples
(0 nM to 2 mM) over flow cells at a flow rate of 40 ml min1.
Response against an ErbB2-coated flow cell was used as a negative
control and subtracted from the response generated against the
ErbB3 ECD to obtain the final sensorgrams. Data was evaluated
using BIAEvaluation 3.2 software (BIAcore, Piscataway, NJ, USA)
and fit using the 1 : 1 Langmuir binding model. Flow cells were
regenerated by sequential 15 s pulses with 10 mM glycine, pH 2, and
50 mM triethylamine, pH 10, followed by equilibration with PBS
running buffer.
Stability of ALM in human serum was assayed as follows. The
A5-linker-ML3.9 bs-scFv was radioiodinated with Iodine-125
(Perkin Elmer, cat no. NEZ033H) using iodogen-coated glass
tubes (Pierce, cat no. 28601) essentially as described (Fraker and
Speck, 1978). Briefly, 300–500 mg of a bs-scFv was labelled with
0.75– 1.35 mCi of Na125I (17 Ci mg1, 350 mCi ml1) containing
10 mM carrier NaI. Labelled protein was purified from non-
incorporated 125I by size-exclusion chromatography over a PD10
column (Amersham Pharmacia) and percentage of incorporation
was determined by ITLC (Biodex). This protocol resulted in
radioiodination of the bs-scFvs at efficiencies between 14 and 42%
and produced product with a specific activity of 0.5–1.3 mCi mg1
that was 495% pure by ITLC. Immunoreactivity of the
radiolabelled bs-scFvs ranged from being 50 to 67% active as
judged by live-cell binding assays with SK-OV-3 cells as described
previously (Adams et al, 1993). Radioiodinated ALM (200 ng ml1)
was diluted 10-fold in human serum (final volume 100ml) and
incubated at 371C over a time course of 72 h. At each time point,
a 10 ml aliquot was removed and retention of activity, as compared
with T¼ 0, was determined by live-cell binding. The FDA-
approved anti-ErbB2 MAb trastuzumab was radioiodinated and
assayed side by side as a positive control.
In vitro selectivity
MDA-MB-468 cells (ErbB2/ErbB3þ ) were stained with 20mM
Cell Tracker Blue CMAC (Molecular Probes, cat no. C-2110),
MVM2 (ErbB2þ /ErbB3) and MCF10a (ErbB2þ /ErbB3þ ) cells
were stained with 10 mM Cell Tracker Orange CMTMR (Molecular
Probes, no. C-2927) and BT-474 cells (ErbB2þ /ErbB3þ ) were left
unstained, as appropriate for each individual experiment. Cells
were plated in six-well plates (300 000 cells per well) and allowed to
adhere overnight. Once adhered, cells were incubated in serum-
free DMEM containing appropriate Cell Tracker dyes for 45 min,
wells were rinsed with Dulbecco’s PBS (Invitrogen, cat. no.
14287072) to remove excess dye and cells were allowed to recover
in DMEM containing 10% FBS for 30 min. Following recovery, cells
were trypsinized and counted. To determine the effect of bivalent
vs monovalent targeting, cells were mixed in equal ratios,
incubated with ALM at concentrations of 1 mM, 0.1 mM, 10 nM,
1 nM or 100 pM for 30 min at 41C, washed with PBS and bound ALM
was detected through its 6XHis tag with an anti-PentaHis-Alexa
Fluor 488 MAb (Qiagen, cat. no. 35310). The samples were
subjected to flow cytometric analysis using either a FACS-LSIIR
equipped with two lasers or a FACS-VantageSE/DiVa machine
(Becton Dickinson) equipped with three lasers, one UV-capable, as
necessary. The forward vs side-scatter parameters were similar for
all the cell lines allowing analysis as a single population. The Blue
cell tracker dye was detected at the Cascade blue channel and the
Orange Cell tracker dye at the PE channel. Three-color flow
cytometry data were acquired using CELLQuest software (Becton
Dickinson) and then analysed using the FlowJo software package
(Tree Star Inc.). Data are representative of three independent
experiments of 9 105cells per sample with X50 000 events
collected. To determine the effect of low-level expression of
both ErbB2 and ErbB3 on ALM targeting, an increasing number of
MCF10a cells were mixed with 2 105 BT-474 cells at ratios of 1 : 1
to 18 : 1, incubated with ALM (100 nM) and analysed by flow
cytometry (1 105 events were collected) as described above.
Biodistribution
Male CB.17 ICR scid mice, 6 –8 weeks of age, were obtained from
the Fox Chase Cancer Center Laboratory Animal Facility, and cells
were implanted as follows. SK-OV-3 (3.0 106), MDA-MB-468
(6.0 106) or MVM-2 (3 106) were implanted subcutaneously
into the inguinal region of the mice. BT-474 (3.0 106) cells were
implanted following subcutaneous implantation of 17-b-estradiol
pellets (Innovative Research of America, cat. no. SE-121). At 3– 7
weeks post-implantation, depending on cell line, tumours were
100–300 mm3 in size. Lugol’s solution (Sigma, cat. no. L6146) was
added to the drinking water at a final concentration of 0.2% to
block thyroid accumulation of radioiodine, and biodistribution
studies were initiated approximately 5 days later. Bispecific
single chain FVS were radioiodinated as described above, and
125I-bs-scFvs (B20 mg per mouse) were administered to cohorts of
mice (nX5 per cohort) through tail-vein injection, mice were
euthanized at indicated times post-injection and dissected, and
major organs were weighed and counted in a g well counter (Cobra
Quantum, Packard Instruments) with a window of 15– 75 keV. The
retention in tumour and non-target tissues was expressed as a
percentage of the injected dose localised per gram of tissue (% ID
per g) as determined from decay-corrected counts as described
previously (Adams et al, 1993). The mean and standard error of
the mean (s.e.m.) values reported are typical results obtained from
at least two replicates of each experimental condition.
In vitro efficacy
MDA-361/DYT2 and BT-474 cells (1.5 105) were plated in six-
well plates (Nunclon, cat. no. 140685) and allowed to adhere
overnight. Cells were left untreated, treated with increasing
concentrations of ALM for 4 days or treated with 4 mM doxorubicin
(Pharmacia & Upjohn) for 24 h. Cells were then analysed for
apoptosis by flow cytometry with the Guava Nexin kit using the
manufacturers protocol. Samples were analysed using a Guava
Technologies Personal cytometer with Annexin V-PE and the
membrane impermeant dye 7-Amino-actinomycin D (7-AAD) as
markers for early and late apoptosis, respectively. Cell cycle
compartment analysis was performed by flow cytometry. Cells
(1 106) were fixed with ice-cold 70% ethanol, treated with
RNaseA (1 mg ml1) for 30 min and then stained with propidium
iodine at a concentration of 50 mg ml1. Cells were analysed by
flow cytometry on a Becton Dickinson FACscan flow cytometer
with CellQuest DNA software. Inhibition of colony formation was
performed as follows. MDA-361/DYT2 and BT-474 were seeded
into six-well plates (6000 cells per well) in a total volume of 2 ml
media and allowed to adhere overnight. In triplicate, media
containing the appropriate antibodies (as described in figure
legends) were added to cells and then refreshed every 5 days. After
2 weeks, colonies were fixed in 70% ethanol and then stained with
0.25% methylene blue and 30% ethanol, and colonies were counted
with an automatic colony counter (MiniCount, IPI Inc.) with a
cutoff of 0.35 mm. Data presented for all in vitro analyses represent
typical results from at least three independent experiments.
Pertuzumab (hu2C4, Genentech) at a concentration of 300 nM
was used as a positive control for these experiments.
Statistical analysis
Average and s.e.m. were calculated for all organs and tumours in
the biodistribution experiments. Averages and standard deviations
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were calculated for apoptosis and colony-forming assays. Unpaired
t-tests were used to determine the statistical significance by using
the online calculator available at the GraphPad Software website
(http://www.graphpad.com/quickcalcs/ContMenu.cfm). P-values
p0.05 were considered to be statistically significant.
RESULTS
Physical characteristics of ALM
To test the hypothesis that bispecific targeting will increase
tumour-targeting selectivity of antibody-based agents, we took
advantage of two previously identified scFv, the anti-ErbB2 ML3.9
scFv (Schier et al, 1996) and the anti-ErbB3 A5 scFv (Horak et al,
2005). The ML3.9 SeFV binds to the ErbB2 ECD with a KD of
1.1 109 M (Schier et al, 1996) and A5 scFv binds to ErbB3 ECD
with a KD of 1.6 107 M (Figure 1) as measured by SPR. To create
ALM, we fused the genes for the two scFv with an oligonucleotide
linker that encodes for a 20 amino acid peptide (Figure 2A). The
A5-linker-ML3.9 bs-scFv is soluble when expressed and secreted
into the periplasmic space of E. coli. Figure 2B depicts a
representative chromatograph of ALM over a Superdex 75 column
following IMAC purification and demonstrating that the majority
(87% in this case) of the protein, as measured by UV absorption, is
located in the monomeric peak. Fractions containing the mono-
meric protein were used for all subsequent analysis. Storage at 41C
for at least 4 weeks does not alter the chromatographic profile of
ALM, and protein can be stored at 801C without an effect on
activity as judged by live-cell binding (data not shown). Fusing the
scFvs into the ‘ALM’ bs-scFv format did not dramatically alter the
antigen-binding kinetics of either scFv. In addition, ALM can bind
simultaneously to both ErbB2 and ErbB3 as measured by SPR
(data not shown). Although somewhat artificial as compared with
binding both antigens on the cell surface, these results indicate that
both arms of the bs-scFv were independently active. Together,
these data supported further in vitro and in vivo evaluation of the
potential for bivalent binding to enhance targeting selectivity.
Further evaluation was also supported by stability of the bs-scFv in
human serum. The A5-linker-ML3.9 bs-scFv retained 92 and 89%
of its ability to bind to ErbB2‘þ ’/ErbB3‘þ ’ SK-OV-3 cells after
48 and 72 h, respectively, when incubated at 371C in human serum
– a time frame compatible with the clearance properties of the
antibody. By comparison, trastuzumab retained B100% of its
activity at 48 h. Consistent with the known biology of ErbB2 and
ErbB3, ALM is internalised upon binding to ErbB2‘þ ’/ErbB3‘þ ’
cells. Within 15 min, 23±0.85% of ALM was internalised, and
by 120 min, 36±0.24% of ALM was internalised with an additional
47±0.16% stably bound to the cell surface.
The A5-linker-ML3.9 bs-scFv selectively targets ErbB2‘þ ’/
ErbB3‘þ ’ cells in vitro
The ability of bivalent association of ALM to promote selective
tumour vs normal tissue uptake was addressed using in vitro, flow
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cytometry-based assays. First, MVM2 cells and MDA-MB-468 were
used to approximate normal tissues that express only ErbB2 or
only ErbB3, respectively, and BT-474 cells represented ErbB2‘þ ’/
ErbB3‘þ ’-positive tumours. The A5-linker-ML3.9 bs-scFv failed
to discriminate between BT-474 (ErbB2‘þ ’/ErbB3‘þ ’) and MVM2
(ErbB2‘þ ’/ErbB3‘’) cell lines at concentrations X100 nM
(Table 2), consistent with high concentrations of ALM favouring
monovalent association with cell lines that overexpress ErbB2. At
10 nM, a concentration approaching the KD of the ML3.9 scFv for
ErbB2, a 3-fold drop in association with MVM2 (ErbB2‘þ ’/
ErbB3‘’) cells was seen with only a corresponding 1.2-fold drop
in association with the BT-474 cells. This resulted in 2.4 times as
many BT-474 (ErbB2‘þ ’/ErbB3‘þ ’) cells bound by ALM as
compared with MVM2 (ErbB2‘þ ’/ErbB3‘’) cells. This difference
in binding was more pronounced at lower concentrations of ALM,
where 6.5 and 9.7 times as many BT-474 cells, as compared with
MVM2 (ErbB2‘þ ’/ErbB3‘’) cells, were bound by ALM at 1 nM
and 100 pM, respectively. Consistent with the low affinity of A5 for
ErbB3, binding to the MDA-MB-468 (ErbB2‘’/ErbB3‘þ ’) cell line
was not detected at concentrations as high as 1 mM.
To model the effects of ErbB2‘þ ’/ErbB3‘þ ’ normal tissue on
ALM targeting, we used fluorescently labelled MCF10a normal
breast epithelial cells mixed with unlabelled BT-474 tumour cells.
MCF10a cells express significantly lower levels of both target
antigens than BT-474 cells (Table 1). MCF10a (ErbB2‘±’/
ErbB3‘±’) and BT-474 (ErbB2‘þ ’/ErbB3‘þ ’) cells were readily
distinguishable by flow cytometry when mixed at both 1 : 1 and
18 : 1 ratios of MCF10a:BT-474 (Figure 3). The A5-linker-ML3.9
bs-scFv (100 nM) specifically bound to BT-474 cells as compared with
the normal MCF10a cells when added to a 1 : 1 mixture of cells. The
A5-linker-ML3.9 bs-scFv was detected in 68.5% of the BT-474 cells,
whereas MCF10a (ErbB2‘±’/ErbB3‘±’) cells failed to exhibit
significant ALM binding. However, ErbB2‘þ ’/ErbB3‘þ ’ normal
cells are predicted to be in vast excess compared with tumour cells
in vivo. To begin to mimic this situation, we incubated ALM with
BT-474 cells that were mixed with increasing numbers of MCF10a
(ErbB2‘±’/ErbB3‘±’) cells. At MCF10a : BT-474 ratios as high as
18 : 1 (maximum ratio tested due to constraints of the assay), the
presence of ‘normal tissue’ had no significant impact on the ability
of ALM to specifically bind to tumour cells. The A5-linker-ML3.9
bs-scFv was detected on 62% of BT-474 (ErbB2‘þ ’/ErbB3‘þ ’)
cells present in the assay without significantly binding to MCF10a
(ErbB2‘±’/ErbB3‘±’) cells despite the 18-fold higher number of
these cells (Figure 3C). This concentration of ALM was capable of
binding monovalently to MVM2 cells in such as way as to prevent
selective binding between BT-474 (ErbB2‘þ ’/ErbB3‘þ ’) and
MVM2 (ErbB2‘þ ’/ErbB3‘’) cells (Table 2). MVM2 (ErbB2‘þ ’/
ErbB3‘’) cells express 3 105 copies of ErbB2 on the cell surface.
This level of expression is equivalent to, or higher than, many
ErbB2-positive breast cancer cells lines, such as MDA-361/DYT2
(3.7 105), T-47D (5.2 104) and MDA-MB-231 (2.8 104) when
measured in vitro by quantitative flow cytometry (Table 1 and
Tang et al, 2007). Together, these data show that ALM is capable of
selectively targeting tumour cells that express high concentrations
of both target antigens over cells that express high levels of only
one target antigen or low levels of both target antigens. In the latter
case, this occurred even when the ErbB2‘þ ’/ErbB3‘þ ’ tumour
cells represented a minority of the total cells in the assay. This
suggests that ALM could exhibit selective tumour-targeting
advantages in the clinical setting where both target antigens are
present at lower concentrations in a number of normal tissues.
The A5-linker-ML3.9 bs-scFv specifically targets
ErbB2‘þ ’/ErbB3‘þ ’ tumours in vivo
Consistent with the proposed hypothesis that bivalent binding will
increase tumour retention, optimal targeting of ALM in vivo
requires expression of both ErbB2 and ErbB3 on the tumour cell
surface (Figure 4A). Radioiodinated ALM (125I-ALM) accumulated
to similar levels (P¼ 0.59) in two different ErbB2‘þ ’/ErbB3‘þ ’
tumour xenografts; 125I-ALM accumulated in BT-474 and SK-OV-3
tumour xenografts at 2.89±0.2 and 3.07±0.27% injected dose per
gram of tissue (% ID per g), respectively, by 24 h post-injection.
These levels are statistically greater than those seen in blood
(Po0.001) or any other tissues analysed (Po0.001) and are
consistent with the rapid targeting selectivity exhibited by anti-
ErbB2 dimeric scFvs against SK-OV-3 xenografts (Adams et al,
2006). Both SK-OV-3 and BT-474 cells express low levels of ErbB3,
as compared with ErbB2 (Table 1). However, SK-OV-3 cells
express levels essentially equal to that of the normal MCF10a
breast cell line, and 10-fold lower than BT-474 cells. This difference
in ErbB3 expression strongly suggests that effective tumour
targeting with bs-scFvs may not require overexpression of both
target antigens relative to normal tissue. Rather, monovalent
association with an overexpressed antigen may be used to drive
initial targeting, with tumour retention being enhanced by avid
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Figure 2 The anti-ErbB2/ErbB3 bs-scFv ALM. (A) Cartoon of ALM
depicting scFv orientation, linker sequence and kinetic constants of ALM for
each target antigen. (B) UV adsorption spectrum chromatograph of ALM
over Superdex 75 size-exclusion column.
Table 2 ALM selectively targets ErbB2/ErbB3 positive cells in vitro
% Positive cellsa
BT-474 MVM2 MDA-MB-468
ALM (ErbB2/ErbB3) (ErbB2/) (/ErbB3)
1mM 99.6 99.2 ND
100 nM 98.6 95.5 ND
10 nM 78.2 32.4 ND
1 nM 23.5 3.6 ND
100 pM 17.0 1.74 ND
Anti-6xHis MAb alone 1.26 1.24 NA
NA¼ not applicable; ND¼ not detectable. aNumbers represent the percentage of
each cell type bound by increasing concentrations of ALM after the three lines were
stained with CellTracker dyes, mixed together in equal numbers, incubated with ALM
and subjected to flow cytometry.
Tumour targeting of an anti-ErbB2/ErbB3 bs-scFv
MK Robinson et al
1419
British Journal of Cancer (2008) 99(9), 1415 – 1425& 2008 Cancer Research UK
T
ra
n
sl
a
ti
o
n
a
l
T
h
e
ra
p
e
u
ti
c
s
binding to the second antigen. Consistent with such a model,
expression of both antigens, and therefore the potential for
divalent binding, is necessary for optimal targeting of ALM.
Despite the fact that ALM was retained in the ErbB2‘þ ’/ErbB3‘’
MVM2 tumours at statistically greater levels than seen in blood
(0.98±0.09 vs 0.28±0.04 %ID/g; Po0.001), the levels of targeting
were significantly lower than those seen in either the BT-474 or
SK-OV-3 xenograft models (Po0.001). Despite the expression of
ErbB3 on the ErbB2‘’/ErbB3‘þ ’ MDA-MB-468 tumour model,
125I-ALM failed to accumulate to levels above that seen in blood
(0.29±0.07 vs 0.29±0.03% ID per g; P¼ 0.55). The inability to
target MDA-MB-468 tumours is consistent with the results of
Adams et al (1998), which demonstrated that effective targeting
and retention of anti-ErbB2 scFv antibodies to SK-OV-3 tumours,
a tumour line that expresses 1 106 copies of ErbB2 per cell,
require a threshold affinity of 1 108 M. The low affinity of the A5
scFv, coupled with the relatively low level of ErbB3 expression
(Table 1), suggests that targeting of ALM to ErbB2‘’/ErbB3‘þ ’
tissues would be minimal.
Undoubtedly, ErbB2 levels play a significant role in ALM
targeting and may explain, at least in part, the lower level of
targeting exhibited against MVM2 tumours, as compared with
either SK-OV-3 or BT-474 tumours. To control for effects of
antigen expression on overall targeting, we constructed bs-scFvs in
which either the A5 scFv or the ML3.9 scFv were replaced with a
‘dead’ (D) scFv specific for a non-natural epitope. Targeting of
these bs-scFvs was then analysed in a single SK-OV-3 (ErbB2‘þ ’/
ErbB3‘þ ’) xenograft model. Targeting of 125I-DLM through the
anti-ErbB2 ML3.9 scFv resulted in 1.55±0.28% ID per g at 24 h
post-injection (Figure 4B), significantly more uptake than seen in
any non-target tissue (Po0.001) but lower than that seen with
ALM (Po0.002). This level of targeting is similar to that displayed
by the isolated ML3.9 scFv (Adams et al, 1998), consistent with
monovalent targeting by DLM. These data again support the
requirement for bivalent association of the bs-scFv with the cell
surface to promote optimal targeting. The A5-linker-ML3.9
bs-scFv targeting of MVM2 (ErbB2‘þ ’/ErbB3‘’) xenografts and
DLM targeting of SK-OV-3 (ErbB2‘þ ’/ErbB3‘þ ’) xenografts, both
driven solely by ErbB2 expression, showed similar levels of uptake
(P¼ 0.089), although the trend favored DLM. This trend may again
reflect the greater level of ErbB2 expression on the SK-OV-3
(ErbB2‘þ ’/ErbB3‘þ ’) cell line. Analogous to the lack of ALM
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Figure 3 The A5-linker-ML3.9 bs-scFv selectively binds BT-474 tumour cells in vitro. Non-labelled BT-474 (ErbB2‘þ ’/ErbB3‘þ ’) breast tumour cells were
mixed with either an equal (A and B) or 18-fold excess (C) of fluorescently labelled MCF10a (ErbB2‘±’/ErbB3‘±’) normal breast epithelial cells. Cell
mixtures were then incubated with buffer (A) or 100 nM ALM (B and C) and binding of ALM to each cell population was determined by flow cytometry
with an anti-6XHis tag secondary antibody. MCF10a cells were sorted to the upper quadrants and the non-labelled BT-474 cells were sorted to the lower
quadrants. Cells bound by the secondary antibody sorted to the respective right hand quadrants. Images on the left depict the raw flow cytometry data.
Values on the right represent the absolute number and overall percentage of each cell type in the respective quadrants.
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targeting seen against MDA-MB-468 (ErbB2‘’/ErbB3‘þ ’) xeno-
grafts, 125I-ALD, which has a functional anti-ErbB3 arm but no
ability to bind to ErbB2, only accumulated to 0.55±0.16% ID per g
in SK-OV-3 (ErbB2‘þ ’/ErbB3‘þ ’) tumours, a level that did not
differ from that seen in blood (P¼ 0.78, Figure 4B). This is again
consistent with the threshold affinity required for effective in vivo
targeting described by Adams et al (1998). The overall variations
in non-target tissue uptake displayed by these bs-scFvs (Figure 4)
may be explained, at least in part, by the process of internalization/
degradation and release of free iodine; all three constructs
displayed the highest degree of variation (s.e.m.¼ 19–43% of
total uptake) in stomach uptake, a tissue that expresses the Na/I
symporter.
The A5-linker-ML3.9 bs-scFv displays intrinsic anti-tumour
cell activity
We hypothesised that targeting the ErbB2/ErbB3 heterodimer with
ALM would have the potential to disrupt downstream signalling
events. Consistent with this hypothesis, treatment of the
ErbB2‘þ ’/ErbB3‘þ ’ BT-474 and MDA-361/DYT2 cells with
250 nM ALM induced apoptosis to a level of B20% as measured
by flow cytometry with Annexin V and 7-AAD, as markers for
early and late apoptosis, respectively (data not shown). Although
the level of apoptosis is modest compared with the 495% seen in
doxorubicin-treated (4 mM) controls, it is greater than the level seen
in non-treated cells and cells treated with an irrelevant control
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Figure 4 Bispecific binding is required for optimal tumour targeting of the ALM bs-scFv in vivo. The biodistributions of radioiodinated ALM, ALD and DLM
bs-scFv were analysed 24 h post-injection into xenograft-bearing SCID mice (n¼ 5 per cohort). (A) Co-expression of ErbB2 and ErbB3 by the targeted
tumour is required for optimal targeting of ALM in vivo. 125I-ALM targeted ErbB2þ /ErbB3þ tumour xenografts to X3-fold higher levels than xenografts
that express only one of the target antigens. (B) Radioiodinated ALM (125I-ALM), which is capable of bivalent association with the surface of Sk-OV-3
tumour cells, exhibited increased targeting as compared with ALD and DLM that targeted the tumours monovalently. Error bars represent the standard
error of the mean (s.e.m.).
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scFv (Po0.001). The low level of apoptosis is similar to that seen
with trastuzumab in certain model systems (Pegram et al, 1999).
More dramatically, ALM treatment inhibits growth of BT-474 and
MDA-361/DYT2 cell lines in standard clonogenicity assays.
Chronic treatment of BT-474 and MDA-361/DYT2 cells with
X50 nM ALM significantly reduced (Po0.001) the ability of the
cells to form colonies in a dose-dependent manner as compared
with vehicle-treated cells (Figure 5A). Treatment with the clinically
relevant MAb pertuzumab (300 nM) inhibited the growth of both
cell lines to similar levels as seen with 50 nM ALM (data not
shown). When taken together, these data suggest that ALM is
eliciting a cytostatic, rather than cytotoxic, effect on the tumour
cells. Consistent with this interpretation, ALM (250 nM) treatment
increased the percentage of MDA-361/DYT2 cells in the G1
compartment of the cell cycle, as compared to cells treated with
either rituximab or vehicle alone (Table 3). As predicted by
published literature (Lewis et al, 1993; Yakes et al, 2002), MDA-
361/DYT2 cells were unresponsive to trastuzumab treatment in
this assay (Table 3).
Interestingly, the therapeutic activity of ALM is almost entirely
because of the anti-ErbB3 A5 arm of the bs-scFv. Chronic
treatment of both BT-474 (Figure 5B) and MDA-361/DYT2
(Figure 5C) cells with A5 scFv significantly inhibited the growth
of the cells in a dose-dependent manner. Although treatment with
ML3.9 produced a modest, although statistically significant, dose-
dependent growth inhibition, the combination of A5 and ML3.9
scFv inhibited the growth of both cell lines to the same extent as A5
alone at all dose levels tested.
DISCUSSION
Classically, bsAbs have been developed to recognise both a
tumour-associated antigen and a ‘trigger antigen’ present on the
surface of an immune effector cell (Adams and Weiner, 2005) with
the aim of redirecting the cytotoxic potential of effector cells
against a patient’s tumour (Weiner et al, 1993; Keler et al, 1997).
Efforts to create such molecules have encompasssed full-length IgG
(Weiner et al, 1993), chemically fused Fab’ fragments (Shalaby
et al, 1992; Keler et al, 1997) and, more recently, small engineered
antibody fragments such as the scFv-based molecules (Shahied
et al, 2004; Molhoj et al, 2007). Preclinical evaluation of these
classes of molecules have demonstrated that bsAbs are capable of
eliciting effector function against HER2-expressing cell lines
in vitro and in animal models. In the case of the anti-HER2/
FcgRIII 2B1 bsAb (Weiner et al, 1993) and the anti-HER2/FcgRI
MDX-H210 bs-Fab, the efficacy in animal models resulted in phase
I clinical trials (Valone et al, 1995; Weiner et al, 1995).
Unlike the bsAbs mentioned above, the ALM bs-scFv antibody
that we describe here binds two distinct tumour-associated
antigens. We hypothesised that the effect of avid binding on the
targeting of small engineered antibodies, as described by Adams
et al (2006), could be exploited to increase targeting selectivity.
Viewed in this context, our data suggest that bispecific binding of
ALM is in fact a major component driving selective targeting of
ALM. In particular, this hypothesis is supported by the in vitro
targeting experiments showing that ALM is capable of selectively
binding ErbB2‘þ ’/ErbB3‘þ ’ tumour cells when present in a
milieu of cells that express either elevated levels of one or normal
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Figure 5 The A5-linker-ML3.9 bs-scFv has intrinsic anti-tumour cell
activity. (A) Treatment of BT-474 and MDA-361/DYT2 cells with ALM
inhibits colony formation in clonogenicity assays. Treatment of (B) BT-474
or (C) MDA-361/DYT2 cells with A5 scFv, ML3.9 scFv or the combination
of both indicates that the majority of the intrinsic anti-tumour cell activity of
ALM is due to the anti-ErbB3 A5 scFv arm. Colonies larger than 0.35 mM
were counted using an automatic colony counter. Error bars represent the
standard deviation.
Table 3 The A5-linker-ML3.9 bs-scFv arrests MDA-361/DYT2 cells in the G1 phase of the cell cycle
% Cells in each cell cycle compartmenta
Treatment G1 S G2
Non-treated 73.8 16.3 12.9
The A5-linker-ML3.9 bs-scFv 85.3 10.4 6.7
Trastuzumab 71.8 18.5 12
Rituximab 74.4 14.1 12.6
aPercentage of cells in each compartment as calculated by the Dean/Jett/Fox algorithm.
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levels of both target antigens. Although the anti-ErbB2 scFv ML3.9
(KD¼ 1 109) was sufficient to promote binding of ALM to
MVM2 cells (ErbB2‘þ ’/ErbB3‘’) at ALM concentrations above
10 nM, it should be noted that MVM2 cells express levels of ErbB2
equal to, or greater than, a number of ErbB2-positive breast cancer
cells lines such as MDA-361/DYT2, T-47D and MDA-MB-231 when
measured in vitro by quantitative flow cytometry (Table 1). The
high level of ErbB2 on MVM2 suggests that the levels of selectivity
obtained may be an underestimate of those obtainable in vivo. This
argument is further supported by the selective targeting of BT-474
cells in a background of excess MCF10a cells. An alternative
possibility, which is not mutually exclusive with the above
hypothesis, is that the anti-ErbB2 scFv ML3.9 is driving initial
ALM targeting and that bispecific binding is promoting selective
retention of ALM. Such a model supports a hypothesis that the use
of moderate- to low-affinity arms in the bs-scFv could significantly
limit targeting of tissues that only express one of the tumour
antigens, particularly when the antigen is expressed at relatively
low levels. Using affinity mutants of the ML3.9 scFv, Adams et al
(1998) have shown that a KD between 10
7 and 108 is necessary to
achieve monovalent targeting in vivo when the antigen is highly
overexpressed. In an effort to optimise the targeting and
therapeutic efficacy of ALM, we hypothesise that strategies to
alter the affinity for either one or both of the arms for their target
antigens can be used to increase the window of selective targeting
achievable with bs-scFvs targeting ErbB2‘þ ’/ErbB3‘þ ’ tumours
although not impairing the overall tumour retention. We believe
that the targeting selectivity exhibited by ALM, coupled with its
intrinsic anti-tumour cell activity and rapid systemic clearance,
makes it a potent therapeutic agent in its own right, as well as an
excellent vehicle for the delivery of toxic payloads, such as
chemotherapy and radionucleotides. Experiments are underway to
test this hypothesis.
Targeting two tumour-associated antigens as a mechanism for
modulating signalling within the tumour cell to elicit a therapeutic
effect was validated by Zu and colleagues using a single-gene
bs-diabody molecule specific for VEGFR2 (KDR) and VEGFR3
(Flt-4). This bs-diabody is capable of binding to both target
receptors and blocking ligand-dependent signalling and cell
migration in vitro (Jimenez et al, 2005). The group has also
elaborated the bs-diabody format to create a di-diabody, a
tetravalent IgG-like structure with an intact Fc-domain. A di-
diabody based on the Vh and Vl domains of the anti-EGFR MAb
IMC-11F8 and the anti-IGFR MAb IMC- 1121 binds to both IGFR
and EGFR. Similar to the parent IgG, the di-diabody blocks ligand-
dependent signalling elicited by both EGF and IGF stimulation and
promotes an ADCC response when assayed in vitro. When injected
into mice harbouring IGFR‘þ ’/EGFR‘þ ’ HT-29 tumour xeno-
grafts, the di-diabody elicits an anti-tumour response that was
statistically similar to that seen in mice treated with a combination
of both parent antibodies (Lu et al, 2005). Elaboration of ALM to
include an intact Fc domain, similar to the di-diabody, may be
useful for future derivatives of ALM to promote prolonged blood
retention and greater tumour uptake, while also providing the
potential for ADCC. Alternatively, strategies such as fusion to
albumin-binding peptides (Dennis et al, 2002; Nguyen et al, 2006)
may be sufficient to increase blood retention, while retaining the
tumour penetration properties of smaller antibody fragments
(Adams and Weiner, 2005).
In contrast to the di-diabody described above, ALM targets a
heterodimeric pair of RTKs from a unique signal transduction
pathway. Misappropriate signalling through the ErbB network
promotes processes such as cell survival and is recognised as
directly contributing to formation and progression of a number of
commonly occurring cancers (Harari and Yarden, 2000; Hynes and
Lane, 2005). Unregulated signalling is often a consequence of
receptor overexpression. In breast cancer driven by gene
amplification and overexpression of ErbB2, disruption of
ErbB2-dependent signalling with either trastuzumab or the
small-molecule tyrosine kinase inhibitor lapatinib is correlated with
clinical efficacy. The ErbB3 growth factor receptor is being
increasingly recognised as a central player in ErbB2-driven breast
cancer. Immunohistochemical studies have shown that ErbB3
is expressed or overexpressed in greater than 50% of DCIS and
invasive breast cancers (Gasparini et al, 1994; Bobrow et al, 1997;
Naidu et al, 1998) and correlates with poor prognosis (Rajkumar
et al, 1996; Lee et al, 2002; Bieche et al, 2003; Witton et al, 2003;
Tovey et al, 2004). As stated above, the ErbB2 and ErbB3
receptors are frequently co-expressed in human breast cancer, but
potentially more indicative of the importance of ErbB2/ErbB3
heterodimers in driving breast cancer progression is the link
between escape from ErbB2-targeted therapies and a gain in ErbB3
activity or expression. In patients, high levels of ErbB3 expression
predict early escape from trastuzumab therapy (Smith et al, 2004),
and escape of at least six different breast cancer cell lines from small-
molecule TKIs in vitro correlates with activation of ErbB3 and
concomitant signalling through the Akt pathway (Sergina et al,
2007). In addition, recent evidence from Lee-Hoeflich et al (2008)
demonstrated that ErbB3 was preferentially phosphorylated in
ErbB2-amplified breast cancer lines and that knockdown of ErbB3
inhibited growth in vitro and in vivo. The authors postulate that the
addition of pertuzumab, an anti-ErbB2 Mab that blocks ligand-
induced ErbB2/ErbB3 dimerisation, to trastuzumab regimens
followed at present may provide additional therapeutic benefit by
inhibiting ErbB3-dependent signalling. The A5-linker-ML3.9 bs-scFv,
by co-targeting this receptor pair, may be capable of a similar
activity.
A number of studies strongly suggest that cross talk between
ErbB2/ErbB3 heterodimer and ER receptor are responsible for
development of tamoxifen resistance (Jhabvala-Romero et al, 2003;
Stoica et al, 2003) and that downregulation of ErbB3 abrogates
tamoxifen resistance (Liu et al, 2007). Similar studies have
linked the ErbB2/ErbB3 heterodimer to the development of
androgen-independent prostate cancer (Mellinghoff et al, 2004;
Ghosh et al, 2005; Gregory et al, 2005; Edwards et al, 2006).
Evidence from lung cancer (Engelman et al, 2007), pancreatic
cancer (Frolov et al, 2007), melanoma (Reschke et al, 2008)
and head and neck cancer (Erjala et al, 2006) suggest that
ErbB3-dependent signalling mechanisms are important for not
only disease progression, but also resistance to EGFR-targeted
therapies. Together, these data support a key role for ErbB3
multiple types of cancer and suggest that effective inhibition
of ErbB3 may be important for gaining complete therapeutic
efficacy with ErbB inhibitors.
The anti-ErbB3 A5 scFv is responsible for the majority of
the intrinsic anti-tumour activity of ALM. Despite an affinity
for ErbB3 that is unable to promote rapid cell binding in either
flow cytometry or in vivo targeting studies, we have shown
that chronic treatment of ErbB3‘þ ’ cells with A5 is sufficient
to induce growth arrest. Thus, by fusing A5 into the ALM bs-scFv,
we have created a vehicle that is capable of effectively targeting
this therapeutic scFv to relevant tumour cells. Although the
molecular mechanism by which A5 induces its therapeutic effect
is not fully elucidated here, one potential mechanism is through
blocking ligand-induced heterodimerization of ErbB3. Consistent
with such a mechanism is the fact that both pertuzumab,
which inhibits ErbB2/ErbB3 heterodimerization and signalling,
and ALM are active preclinically against breast cancer cells that
are not gene-amplified for ErbB2. This is in direct contrast to the
FDA-approved MAb trastuzumab, which requires ErbB2 gene
amplification.
In conclusion, we have created a bs-scFv molecule that is
capable of mediating selective in vitro and in vivo tumour targeting
and provided what we believe to be the first rigorous evidence of
enhanced targeting selectivity by a bsAb specific for two tumour-
associated antigen (TAA). The consequence of targeting tumour
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cells with ALM is effective inhibition of tumour cell growth
in vitro. Taken together, our results suggest that bispecific
targeting of ErbB2 and ErbB3 with ALM may be efficacious
in vivo against breast cancers with a wider range of ErbB2
expression than those amenable to the trastuzumab therapy
available at present. We are addressing this question at present.
Moreover, these data also suggest that targeting strategies that
depend upon co-expression of two TAAs such as the one used here
may increase tumour-targeting specificity and decrease the normal
tissue toxicities that are sometimes associated with antibody-based
targeting of growth factor receptors. Furthermore, the clearance
kinetics of ALM, coupled with its targeting selectivity, may make it
an excellent candidate for use as an immunoconjugate for the
delivery of cytotoxic agents.
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